Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE318.1027.2 (+9.35 % )
PREV CLOSE (Rs.) 290.90
OPEN PRICE (Rs.) 300.10
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 520639
TODAY'S LOW / HIGH (Rs.)298.05 319.95
52 WK LOW / HIGH (Rs.)211.3 323.3
NSE318.30 27.35 (+9.4 % )
PREV CLOSE(Rs.) 290.95
OPEN PRICE (Rs.) 300.00
BID PRICE (QTY) 318.30 (4241 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 9742331
TODAY'S LOW / HIGH(Rs.) 297.30 320.00
52 WK LOW / HIGH (Rs.)211.05 323.5

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.16
TTM EPS (Rs.) 3.44
P/E Ratio 92.38
Book Value (Rs.) 61.94
Face Value (Rs.) 5
MCap (Rs. in Mn) 381720.00
Price/Earning (TTM) 72.83
Price/Sales (TTM) 16.82
Price/Book (MRQ) 5.14
PAT Margin (%) 17.08
ROCE (%) 7.89
Incorporation Year : 1978

Management Info :

Kiran Mazumdar-Shaw - Chairman Kiran Mazumdar-Shaw - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 080 2808 2808

Website : www.biocon.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
01Apr04-01-2020$Biocon’s arm receives EIR from USFDA for Malaysia facility Biocon’s arm receives EIR

Biocon subsidiary -- Biocon Sdn Bhd has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) of its Insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between February 10 and February 21, 2020.

The Inspection has been closed with a ‘VAI’ (Voluntary Action Indicated) classification in the EIR, for the three observations issued at the conclusion of the inspection in Feb 2020.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon subsidiary -- Biocon Sdn Bhd has received the Establishm..
01Apr04-01-2020$Biocon gains on receiving EIR from USFDA for Malaysia facility Biocon gains on receiving EI
Biocon is currently trading at Rs. 276.35, up by 5.75 points or 2.12% from its previous closing of Rs. 270.60 on the BSE.

The scrip opened at Rs. 280.00 and has touched a high and low of Rs. 285.40 and Rs. 274.55 respectively. So far 91051 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 323.30 on 24-Feb-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.

Last one week high and low of the scrip stood at Rs. 290.50 and Rs. 268.20 respectively. The current market cap of the company is Rs. 33150.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.64% and 17.70% respectively.

Biocon subsidiary -- Biocon Sdn Bhd has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) of its Insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between February 10 and February 21, 2020.

The Inspection has been closed with a ‘VAI’ (Voluntary Action Indicated) classification in the EIR, for the three observations issued at the conclusion of the inspection in Feb 2020.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is currently trading at Rs. 276.35, up by 5.75 points or..
27Mar03-27-2020$Biocon, its arm ensuring manufacturing of life-saving medicines for patients Biocon, its arm ensuring man

Biocon and its subsidiary -- Biocon Biologics -- have activated business continuity plans across their functions to prepare for unforeseen events in light of the evolving COVID19 situation and to meet the needs of patients, partners, customers and other stakeholders who depend on their products.

The government of India has announced a 21-day nationwide lockdown on March 24, 2020, but permitted ‘essential services’ such as manufacturing of pharmaceuticals to continue. The company will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon and its subsidiary -- Biocon Biologics -- have activated..
20Mar03-20-2020$Biocon receives EIR from USFDA for manufacturing facility in Bengaluru Biocon receives EIR from USF

Biocon has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between February 20, 2020 and February 26, 2020.

The EIR has been closed with a VAI classification for the observations. At the conclusion of the inspection in February, the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the company.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon has received the Establishment Inspection Report (EIR) f..
20Mar03-20-2020$Biocon informs about company updates Biocon informs about company

Biocon has informed that the company has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between Feb 20 and Feb 26, 2020. The EIR has been closed with a VAI classification for the observations. At the conclusion of the inspection last month the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the Company.

The above information is a part of company’s filings submitted to BSE.

Biocon has informed that the company has received the Establish..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit12074927
Gross Profit 1578 5521
Operating Profit 12825031
Net Sales 501328847
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 16722.05 (5.66%)
M.Cap ( in Cr)
35533.19
Procter&Gamble Healt (BSE)
 4324.60 (11.90%)
M.Cap ( in Cr)
7178.57
Dr. Reddys Lab (BSE)
 3583.15 (13.94%)
M.Cap ( in Cr)
59541.95
Sanofi India (BSE)
 7023.75 (5.40%)
M.Cap ( in Cr)
16176.13
Astrazeneca Pharma I (BSE)
 2694.10 (12.08%)
M.Cap ( in Cr)
6735.25
Shareholding Pattern More
PROMOTERS 60.67 %
MUTUAL FUNDS/UTI 3.76 %
NON-INSTITUTION 17.7 %
FI/BANKS/INSURANCE 1.33 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes